Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for bone mineral density in multiple sclerosis patients with osteoporosis or osteopenia
2009-011888-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis and osteopenia comparing Aclasta with Placebo (2 arms). Primary endpoints: Change in lumbar spine bone mineral density T-score and Change in total hip bone mineral density T-score. Started Mar 2010; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on 2009-011888-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011888-37.